ArticleBMC infectious diseases2026
Temporal trends in RSV-specific antibody seroprevalence among hosptalized children during the COVID-19 pandemic in Japan: a retrospective cross-sectional study.
Article in BMC infectious diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Respiratory syncytial virus (RSV) is a major cause of acute respiratory illness in young children. Given the transient nature of natural immunity, understanding age-specific seroprevalence is critical for optimising vaccine development and strategies. This study investigated the impact of the COVID-19 pandemic on RSV immunity in children under five (0–60 months), specifically aiming to determine the age with the lowest antibody prevalence and assess overall RSV seroprevalence during the pandemic years (2019–2021). Analysis of serum IgG concentrations revealed a significant decline in overall RSV IgG levels and seropositivity rates. Median IgG concentrations dropped from 912.94 mIU/mL in 2019 to 527.74 mIU/mL in 2021 (p < 0.001). A one-way ANOVA confirmed a significant effect of year on IgG levels (p < 0001), with post-hoc Tukey HSD tests showing significant differences between all annual pairs (2019 vs 2020: p < 0.0001; 2020 vs 2021: p = 0.0015). Age-stratified analysis consistently showed a U-shaped pattern in mean log IgG levels across all years: high in young infants (maternal antibodies), declining through early childhood, and increasing in older children. The IgG lowest point was delayed in 2021 (9–12 months) versus 2019 (5–8 months). Consistently lower IgG levels and seropositivity rates were observed in 2020 and 2021. Peak second quarter seropositivity dropped from 50.0–50.3% (2019–2020) to 25.0% (2021), and older children’s peak seropositivity in 2021 was 47.0% vs. 85.0% in 2019. These findings suggest that reduced RSV circulation during the COVID-19 pandemic may have yielded lower RSV-specific antibody levels among hospitalized children. While not representative of the general pediatric population, these results highlight the value of hospital-based serological monitoring to detect shifts in viral exposure and inform immunization strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.